Cargando…

Implications of drugs with rebate in Europe

Detalles Bibliográficos
Autores principales:	Bonetti, Andrea, Giuliani, Jacopo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454721/ https://www.ncbi.nlm.nih.gov/pubmed/34557803 http://dx.doi.org/10.1016/j.lanepe.2021.100060

Ejemplares similares

Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe
por: Carl, David L, et al.
Publicado: (2021)

Footing the bill: the introduction of Medicare Benefits Schedule rebates for podiatry services in Australia
por: Short, Anthony J
Publicado: (2009)

Argumentación rebatible : modelos y aplicaciones
por: Bodanza, Gustavo Adrián
Publicado: (2011)

Claim for Rebate of Spirit Duty
por: Churchfield, Jas. M.
Publicado: (1917)

Physicians’ Rebate Check-Book
Publicado: (1892)

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
por: Giuliani, Jacopo, et al.
Publicado: (2021)

The effect of COVID-19 pandemic on daily oncology clinical practice
por: Codacci-Pisanelli, Giovanni, et al.
Publicado: (2021)

The Relative Value of Disease Management Programs Versus Drug Manufacturer Rebates
por: Curtiss, Frederic R.
Publicado: (2003)

Premium Rebates and the Quiet Consensus on Market Reform for Medicare
por: Feldman, Roger, et al.
Publicado: (2001)

Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019
por: Plummer, Elizabeth, et al.
Publicado: (2022)

Paediatric genomic testing: Navigating medicare rebatable genomic testing
por: Sachdev, Rani, et al.
Publicado: (2021)

Discounts and rebates granted to public payers for medicines in European countries
por: Vogler, Sabine, et al.
Publicado: (2012)

Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018
por: Lakdawalla, Darius, et al.
Publicado: (2021)

Pressure on Pharmacy Benefit Managers for Disclosure and Demonstration of Value - Rebates and Drug Benegit Cost Savings
por: Curtiss, Frederic R.
Publicado: (2003)

Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs
por: Wong, William Bruce, et al.
Publicado: (2023)

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates
por: Espin, Jaime, et al.
Publicado: (2018)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Regulating the health workforce in Europe: implications of the COVID-19 pandemic
por: Panteli, Dimitra, et al.
Publicado: (2021)

Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018
por: Yeung, Kai, et al.
Publicado: (2021)

Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer
por: Hernandez, Inmaculada, et al.
Publicado: (2020)

An exploration of rollover protective structures (ROPS) rebate program media coverage: strategies for implementation and sustainment
por: Tinc, Pamela J., et al.
Publicado: (2019)

Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019
por: Clemans-Cope, Lisa, et al.
Publicado: (2023)

Drink Driving as the Commonest Drug Driving—A Perspective from Europe
por: Allsop, Richard
Publicado: (2020)

Impact of the Medicare Benefits Schedule Rebate (MBSR) freeze on General Practice (GP) use: multivariable regression analysis
por: Mudiyanselage, Shalika Bohingamu, et al.
Publicado: (2023)

Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe
por: Kautz, Achim, et al.
Publicado: (2014)

Opportunities for vaccine research in Europe
por: Gancberg, David, et al.
Publicado: (2015)

Positioning Europe for the EPITRANSCRIPTOMICS challenge
por: Jantsch, Michael F., et al.
Publicado: (2018)

Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial
por: Bilger, Marcel, et al.
Publicado: (2019)

Cancer Control in Central and Eastern Europe
por: La Vecchia, Carlo, et al.
Publicado: (2016)

Population birth data and pandemic readiness in Europe
por: Rodin, Urelija, et al.
Publicado: (2021)

The impact of COVID-19 on primary care in Europe
por: Mughal, Faraz, et al.
Publicado: (2021)

PrEP in Europe – expectations, opportunities and barriers
por: McCormack, Sheena Mary, et al.
Publicado: (2016)

Opportunities and challenges in rheumatology research in Central Europe
por: Szekanecz, Zoltán, et al.
Publicado: (2017)

Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology
por: Baldo, Paolo, et al.
Publicado: (2018)

Disease-modifying drugs for Alzheimer disease: implications for people in Canada
por: Watt, Jennifer A., et al.
Publicado: (2023)

Populism and Health Policy in Latin America Comment on "A Scoping Review of Populist Radical Right Parties’ Influence on Welfare Policy and its Implications for Population Health in Europe"
por: Clark, Mary A., et al.
Publicado: (2020)

Who Deserves Welfare and Who Does Not? Comment on "A Scoping Review of Populist Radical Right Parties’ Influence on Welfare Policy and its Implications for Population Health in Europe"
por: Muis, Jasper
Publicado: (2020)

A network strategy to advance public health in Europe
por: Semenza, Jan C., et al.
Publicado: (2008)

Geographical differences on the mortality impact of heat waves in Europe
por: Sunyer, Jordi
Publicado: (2010)

Opinion: why the variation in breast cancer survival in Europe?
por: Coleman, Michel P
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_nkdpbnfkkq3otnsq33sd71mhh0